Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults

Journal of Neuroscience Research

Volumn 82, Issue 2, 2005, Pages 232-244

  Hyun, Dong Hoon ^a,c   Lee, MoonHee ^a   Halliwell, Barry ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Autosomal recessive juvenile parkinsonism; Oxidative stress; Wild type and mutant parkins

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYGUANINE; CARBONYL DERIVATIVE; HYDROGEN PEROXIDE; LACTACYSTIN; PARKIN; PROTEASOME INHIBITOR; PYRIDINIUM DERIVATIVE;

APOPTOSIS; ARTICLE; ATTENUATION; CELL DAMAGE; CELL DEATH; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; SERUM; SUBSTANTIA NIGRA; WILD TYPE;

1-METHYL-4-PHENYLPYRIDINIUM; ACETYLCYSTEINE; ALDEHYDES; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE; ENZYME INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; GUANINE; HUMANS; HYDROGEN PEROXIDE; MUTATION; NERVE DEGENERATION; NEURONS; NEUROTOXINS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA; TYROSINE; UBIQUITIN-PROTEIN LIGASES;

EID: 27844554819     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20638     Document Type: Article

References (65)

1. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. 1997a. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69:1326-1329.
2. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B. 1997b. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69:1196-1203.
3. Angulo A, Suto C, Ghazal P. 1995. Retinoid activation of retinoic acid receptors but not of retinoid X receptors promotes cellular differentiation and replication of human cytomegalovirus in embryonal cells. J Virol 69:3831-3837.
4. Ardley HC, Scott GB, Rose SA, Tan NG, Markham AF, Robinson PA. 2003. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. Mol Biol Cell 14:4541-4556.
5. Beal MF. 1997. Oxidative damage in neurodegenerative diseases. Neuroscience 3:21-27.
6. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-1555.
7. Biedler JL, Roffler-Tarlov S, Schner M, Freeman LS. 1978. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38:3751-3757.
8. Bjorklund A, Rosenblad C, Winkler C, Kirik D. 1997. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200.
9. Cadenas E, Davies KJ. 2000. Mitochondrial free radical generation, oxidative stress, and aging. Free Rad Biol Med 29:222-230.
10. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P. 2000. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 20:589-599.
11. Chirico S. 1994. High-performance liquid chromatography-based thiobarbituric acid tests. Methods Enzymol 233:314-318.
12. Cohen G, Farooqui R, Kesler N. 1997. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A 94:4890-4894.
13. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M, Brice A. 2003. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12:517-526.
14. Fenteany G, Schreiber SL. 1998. Lactacystin, proteasome function and cell fate. J Biol Chem 273:8545-8548.
15. Grune T, Blasig IE, Sitte N, Roloff B, Haseloff R, Davies KJ. 1998. Peroxynitrite increases the degradation of aconitase and other cellular proteins by proteasome. J Biol Chem 273:10857-10862.
16. Grune T, Merker K, Sandig G, Davies KJ. 2003. Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 305:709-718.
17. Halliwell B. 1997. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 411:157-160.
18. Halliwell B, Jenner P. 1998. Impaired clearance of oxidised proteins in neurodegenerative diseases. Lancet 351:1510.
19. Halliwell B. 2001. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716.
20. Halliwell B, Whiteman M. 2004. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 142:231-255.
21. Harlow E, Lane D. 1988. Antibodies: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
22. Hattori N, Kitada T, Matsumine H, Asakawa S, Yamamura Y, Yoshino H, Kobayashi T, Yokochi M, Wang M, Yoritaka A, Kondo T, Kuzuhara S, Nakamura S, Shimizu N, Mizuno Y. 1998a. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 44:935-941.
23. Hattori N, Matsumine H, Asakawa S, Kitada T, Yoshino H, Elibol B, Brookes AJ, Yamamura Y, Kobayashi T, Wang M, Yoritaka A, Minoshima S, Shimizu N, Mizuno Y. 1998b. Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res Commun 249:754-758.
24. Hyun D-H, Lee M, Halliwell B, Jenner P. 2002. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses and the proteasome. J Biol Chem 277:28572-28577.
25. Hyun D-H, Lee M, Halliwell B, Jenner P. 2003. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem 86:363-373.
26. Jenner P, Olanow CW. 1998. Understanding cell death in Parkinson's disease. Ann Neurol 44(Suppl 1):S72-S84.
27. Jesenberger V, Jentsch S. 2002. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3:112-121.
28. Junn E, Lee SS, Suhr UT, Mouradian MM. 2002. Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 277:47870-47877.
29. Kaur H, Halliwell B. 1996. Measurement of oxidized and methylated DNA bases by HPLC with electrochemical detection. Biochem J 318: 21-23.
30. Kelner GS, Lee M, Clark ME, Maciejewski D, McGrath D, Rabizadeh S, Lyons T, Bredesen D, Jenner P, Maki RA. 2000. The copper transport protein Atox1 promotes neuronal survival. J Biol Chern 275:580-584.
31. Khan J, Brennand DM, Bradley N, Gao B, Bruckdorfer R, Jacobs M. 1998. 3-Nitrotyrosine in the proteins of human plasma determined by an ELISA method. Biochem J 332:807-808.
32. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
33. Klein C, Schumacher K, Jacobs H, Hagenah J, Kis B, Garrels J, Schwinger E, Ozelius L, Pramstaller P, Vieregge P, Kramer PL. 2000a. Association studies of Parkinson's disease and parkin polymorphisms. Ann Neurol 48:126-127.
34. Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. 2000b. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 48:65-71.
35. Kruger R, Vieira-Sacker AM, Kuhn W, Muller T, Woitalla D, Schols L, Przuntek H, Epplen JT, Riess O. 1999. Analysis of the parkin deletion in sporadic and familial Parkinson's disease. Short communication. J Neural Transm 106:159-163.
36. Lee M, Hyun D-H, Jenner P, Halliwell B. 2001a. Effect of overexpression of wild type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J Neurochem 76:957-965.
37. Lee M, Hyun D-H, Halliwell B, Jenner P. 2001b. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76:998-1009.
38. Lee M, Hyun D-H, Jenner P, Halliwell B. 2001c. Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J Neurochem 78:32-41.
39. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
40. Lyras L, Evans PJ, Shaw PJ, Ince PG, Halliwell B. 1996. Oxidative damage and motor neuron disease: difficulties in the measurement of protein carbonyls in human brain tissue. Free Rad Res 24:397-406.
41. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B. 1997. An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease. J Neurochem 68:2061-2069.
42. Lyras L, Perry RH, Perry EK, Ince PG, Jenner A, Jenner P, Halliwell B. 1998. Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J Neurochem 71:302-312.
43. McNaught KS, Jenner P. 2001. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297:191-194.
44. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2:589-594.
45. Mezey E, Dehejia A, Harta G, Papp MI, Polymeropoulos MH, Brownstein MJ. 1998. α-Synuclein in neurodegenerative disorders, murderer or accomplice? Nat Med 4:755-759.
46. Nisipeanu P, Inzelberg R, Blumen SC, Carasso RL, Hattori N, Matsumine H, Mizuno Y. 1999. Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of Parkin gene. Neurology 53:1602-1604.
47. Oliver CN, Starke-Reed PE, Stadtman ER, Liu GJ, Carney JM, Floyd RA. 1990. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci U S A 87:5144-5147.
48. Ong WY, Halliwell B. 2004. Iron, atherosclerosis, and neurodegeneration: a key role for cholesterol in promoting iron-dependent oxidative damage? Ann N Y Acad Sci 1012:51-64.
49. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J. 2004. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614-18622.
50. Petruceffi L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR. 2002. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36:1007-1019.
51. Reznick AZ, Packer L. 1994. Oxidative damage to proteins, spectrophotometric methods for carbonyl assay. Methods Enzymol 223:357-363.
52. Schapira AH. 1994. Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Mov Disord 9:125-138.
53. Shang F, Nowell TR Jr, Taylor A. 2001. Removal of oxidatively damaged proteins from lens cells by the ubiquitin-proteasome pathway. Exp Eye Res 73:229-238.
54. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302-305.
55. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. 1994. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 36:56-66.
56. Singer TP, Castagnoli N Jr, Ramsey RR, Trevor AJ. 1987. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1, b,c,6-tetrahydropyridine. J Neurochem 49:1-8.
57. Sitte N, Merker K, von Zglinicki T, Grune T. 2000. Protein oxidation and degradation during proliferative senescence of human MRC-5 fibroblasts. Free Rad Biol Med 28:701-708.
58. Stadtman ER, Berlett BS. 1998. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev 30:225-243.
59. Stefani L, Burke RE, Greene LA. 1997. Apoptosis in neurodegenerative disorders. Curr Opin Neurol 10:299-305.
60. Takanashi M, Mochizuki H, Yokomizo K, Hattori N, Mori H, Yamamura Y, Mizuno Y. 2001. Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism. Parkinsonism Rel Disord 7: 311-314.
61. Wesselborg S, Kabelitz D. 1993. Activation-driven death of human T cell clones: time-course kinetics of the induction of cell shrinkage, DNA fragmentation, and cell death. Cell Immunol 148:234-241.
62. Whiteman M, Halliwell B. 1999. Loss of 3-nitrotyrosine on exposure to hypochlorous acid: Implications for the use of 3-nitrotyrosine as a biomarker in vivo. Biochem Biophys Res Commun 258:168-172.
63. Yanagihara K, Tsumuraya M. 1992. Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 52:4042-4045.
64. Yermilov V, Rubio J, Ohshima H. 1995. Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. FEBS Lett 376:207-210.
65. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. 1996. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93:2696-2701.